Advertisement

Topics

Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma

2014-10-03 16:35:38 | BioPortfolio

Published on BioPortfolio: 2014-10-03T16:35:38-0400

Clinical Trials [3710 Associated Clinical Trials listed on BioPortfolio]

A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma

To examine whether the arginine depleting drug, ADI-PEG 20, might be effective as a targeted therapy in patients with ASS-negative malignant pleural mesothelioma.

IP3R Modulation by Cancer Genes in Mesothelioma

Obtaining pleural biopsies in cases of malignant mesothelioma to detect molecular mechnisms and signal transduction

Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma

Malignant pleural mesothelioma (MPM) is an aggressive tumour with poor prognosis (median survival

Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity

For patients with malignant pleural mesothelioma that has grown despite treatment with standard chemotherapy, no treatment has yet proven beneficial. The purpose of this study is to find o...

Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma

The purpose of this study is to determine whether the transarterial chemoperfusion treatment with cisplatin, methotrexate and gemcitabine is safe and effective in adults with malignant ple...

PubMed Articles [16870 Associated PubMed Articles listed on BioPortfolio]

PD-1 blockade with nivolumab in patients with recurrent Malignant Pleural Mesothelioma.

Malignant Pleural Mesothelioma (MPM) has limited treatment options and a poor outcome. PD-1/PD-L1 checkpoint inhibitors have proven efficacious in several cancer types. Nivolumab is a fully humanized ...

Utility of Site-Specific Biopsy for Diagnosis of Desmoplastic Malignant Mesothelioma.

Desmoplastic malignant mesothelioma (DMM) is a relatively rare histological subtype of malignant pleural mesothelioma (MPM). Among MPMs, the diagnosis of DMM is particularly difficult because the tumo...

NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.

Malignant pleural mesothelioma is an aggressive cancer with highly vascularised tumours. It has poor prognosis and few treatment options after failure of first-line chemotherapy. NGR-hTNF is a vascula...

Procedure-related tumour seeding in lung cancer with malignant pleural effusion: Radiological features and outcomes.

Pleural procedures are performed to prove the diagnosis of pleural effusion. This study was to assess the incidence and outcome of pleural procedure-related tumour seeding in lung cancer with malignan...

A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma.

The primary objective of this single-institution Phase I clinical trial was to establish the maximum tolerated dose (MTD) of gemcitabine added to cisplatin delivered as heated intraoperative chemother...

Medical and Biotech [MESH] Definitions

Presence of fluid in the PLEURAL CAVITY as a complication of malignant disease. Malignant pleural effusions often contain actual malignant cells.

A peritoneal mesothelioma affecting mainly young females and producing cysts of variable size and number lined by a single layer of benign mesothelial cells. The disease follows a benign course and is compatible with a normal life expectancy, requiring occasionally partial excision or decompression for relief of pain or other symptoms. Malignant potential is exceptional. (From Holland et al., Cancer Medicine, 3d ed, p1345)

A rare neoplasm, usually benign, derived from mesenchymal fibroblasts located in the submesothelial lining of the PLEURA. It spite of its various synonyms, it has no features of mesothelial cells and is not related to malignant MESOTHELIOMA or asbestos exposure.

Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.

The phosphoprotein encoded by the BRCA1 gene (GENE, BRCA1). In normal cells the BRCA1 protein is localized in the nucleus, whereas in the majority of breast cancer cell lines and in malignant pleural effusions from breast cancer patients, it is localized mainly in the cytoplasm. (Science 1995;270(5237):713,789-91)

More From BioPortfolio on "Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial